263 related articles for article (PubMed ID: 33939332)
1. Glasgow prognostic score for prediction of chemotherapy-triggered acute exacerbation interstitial lung disease in patients with small cell lung cancer.
Kikuchi R; Takoi H; Tsuji T; Nagatomo Y; Tanaka A; Kinoshita H; Ono M; Ishiwari M; Toriyama K; Kono Y; Togashi Y; Yamaguchi K; Yoshimura A; Abe S
Thorac Cancer; 2021 Jun; 12(11):1681-1689. PubMed ID: 33939332
[TBL] [Abstract][Full Text] [Related]
2. Glasgow Prognostic Score predicts chemotherapy-triggered acute exacerbation-interstitial lung disease in patients with non-small cell lung cancer.
Kikuchi R; Takoi H; Tsuji T; Nagatomo Y; Tanaka A; Kinoshita H; Ono M; Ishiwari M; Toriyama K; Kono Y; Togashi Y; Yamaguchi K; Yoshimura A; Abe S
Thorac Cancer; 2021 Mar; 12(5):667-675. PubMed ID: 33480111
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy-associated Acute Exacerbation of Interstitial Lung Disease Shortens Survival Especially in Small Cell Lung Cancer.
Nakao S; Yamaguchi K; Sakamoto S; Horimasu Y; Masuda T; Miyamoto S; Nakashima T; Iwamoto H; Fujitaka K; Hamada H; Hattori N
Anticancer Res; 2019 Oct; 39(10):5725-5731. PubMed ID: 31570474
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of preexisting interstitial lung disease in Japanese patients with small-cell lung cancer.
Togashi Y; Masago K; Handa T; Tanizawa K; Okuda C; Sakamori Y; Nagai H; Kim YH; Mishima M
Clin Lung Cancer; 2012 Jul; 13(4):304-11. PubMed ID: 22169479
[TBL] [Abstract][Full Text] [Related]
5. The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancer.
Masuda T; Hirano C; Horimasu Y; Nakashima T; Miyamoto S; Iwamoto H; Ohshimo S; Fujitaka K; Hamada H; Hattori N
Cancer Chemother Pharmacol; 2018 Jan; 81(1):131-139. PubMed ID: 29143072
[TBL] [Abstract][Full Text] [Related]
6. The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer.
Kenmotsu H; Naito T; Kimura M; Ono A; Shukuya T; Nakamura Y; Tsuya A; Kaira K; Murakami H; Takahashi T; Endo M; Yamamoto N
J Thorac Oncol; 2011 Jul; 6(7):1242-6. PubMed ID: 21623239
[TBL] [Abstract][Full Text] [Related]
7. Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer.
Hamada S; Ichiyasu H; Ikeda T; Inaba M; Kashiwabara K; Sadamatsu T; Sato N; Akaike K; Okabayashi H; Saruwatari K; Tomita Y; Saeki S; Hirata N; Yoshinaga T; Fujii K
BMC Pulm Med; 2019 Apr; 19(1):72. PubMed ID: 30940113
[TBL] [Abstract][Full Text] [Related]
8. Low forced vital capacity predicts cytotoxic chemotherapy-associated acute exacerbation of interstitial lung disease in patients with lung cancer.
Enomoto Y; Inui N; Kato T; Baba T; Karayama M; Nakamura Y; Ogura T; Suda T
Lung Cancer; 2016 Jun; 96():63-7. PubMed ID: 27133752
[TBL] [Abstract][Full Text] [Related]
9. ILD-NSCLC-GAP index scoring and staging system for patients with non-small cell lung cancer and interstitial lung disease.
Kobayashi H; Naito T; Omae K; Omori S; Nakashima K; Wakuda K; Ono A; Kenmotsu H; Murakami H; Endo M; Takahashi T
Lung Cancer; 2018 Jul; 121():48-53. PubMed ID: 29858026
[TBL] [Abstract][Full Text] [Related]
10. Peripheral-type small cell lung cancer is associated with better survival and higher frequency of interstitial lung disease.
Kanaji N; Sakai K; Ueda Y; Miyawaki H; Ishii T; Watanabe N; Kita N; Kadota K; Kadowaki N; Bandoh S
Lung Cancer; 2017 Jun; 108():126-133. PubMed ID: 28625624
[TBL] [Abstract][Full Text] [Related]
11. Disease activity of lung cancer at the time of acute exacerbation of interstitial lung disease during cytotoxic chemotherapy.
Sekine A; Matama G; Hagiwara E; Tabata E; Ikeda S; Oda T; Okuda R; Kitamura H; Baba T; Satoh H; Misumi T; Komatsu S; Iwasawa T; Ogura T
Thorac Cancer; 2022 Sep; 13(17):2443-2449. PubMed ID: 35840339
[TBL] [Abstract][Full Text] [Related]
12. Idiopathic pulmonary fibrosis in small cell lung cancer as a predictive factor for poor clinical outcome and risk of its exacerbation.
Koyama N; Iwai Y; Nagai Y; Aoshiba K; Nakamura H
PLoS One; 2019; 14(8):e0221718. PubMed ID: 31442290
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of
Akaike K; Saruwatari K; Oda S; Shiraishi S; Takahashi H; Hamada S; Iyama S; Horio Y; Tomita Y; Saeki S; Okamoto S; Ichiyasu H; Fujii K; Sakagami T
Int J Clin Oncol; 2020 Apr; 25(4):681-690. PubMed ID: 31781994
[TBL] [Abstract][Full Text] [Related]
14. Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease.
Kenmotsu H; Naito T; Mori K; Ko R; Ono A; Wakuda K; Imai H; Taira T; Murakami H; Endo M; Takahashi T
Cancer Chemother Pharmacol; 2015 Mar; 75(3):521-6. PubMed ID: 25563718
[TBL] [Abstract][Full Text] [Related]
15. The ATS/ERS/JRS/ALAT statement "IPF by HRCT" could predict acute exacerbation of interstitial lung disease in non-small cell lung cancer.
Asai N; Katsuda E; Hamanaka R; Kosaka K; Matsubara A; Nishimura M; Tanaka H; Yokoe N; Takahashi A; Yamaguchi E; Kubo A
Tumori; 2017 Jan; 103(1):60-65. PubMed ID: 27791236
[TBL] [Abstract][Full Text] [Related]
16. The utility of ground-glass attenuation score for anticancer treatment-related acute exacerbation of interstitial lung disease among lung cancer patients with interstitial lung disease.
Nishiyama N; Honda T; Sema M; Kawahara T; Jin Y; Natsume I; Chiaki T; Yamashita T; Tsukada Y; Taki R; Miyashita Y; Saito K; Tateishi T; Sakashita H; Miyazaki Y
Int J Clin Oncol; 2020 Feb; 25(2):282-291. PubMed ID: 31720993
[TBL] [Abstract][Full Text] [Related]
17. Impact of sarcopenia on chemotherapy-triggered exacerbation of interstitial lung disease in patients with non-small cell lung cancer.
Kikuchi R; Takoi H; Ishiwari M; Toriyama K; Kono Y; Togashi Y; Abe S
Thorac Cancer; 2022 Feb; 13(4):549-556. PubMed ID: 34964266
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and risk of cytotoxic chemotherapy in extensive disease-small cell lung cancer patients with interstitial pneumonia.
Shirasawa M; Fukui T; Kusuhara S; Hiyoshi Y; Nakahara Y; Nishinarita N; Igawa S; Naoki K
BMC Cancer; 2019 Feb; 19(1):163. PubMed ID: 30808322
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of serum oncomarkers for patients hospitalized with acute exacerbation of interstitial lung disease.
Ba C; Jiang C; Wang H; Shi X; Jin J; Fang Q
Ther Adv Respir Dis; 2024; 18():17534666241250332. PubMed ID: 38757948
[TBL] [Abstract][Full Text] [Related]
20. Analysis of acute exacerbation of interstitial lung disease associated with chemotherapy in patients with lung cancer: A feasibility of S-1.
Kakiuchi S; Hanibuchi M; Tezuka T; Saijo A; Otsuka K; Sakaguchi S; Toyoda Y; Goto H; Kawano H; Azuma M; Ogushi F; Nishioka Y
Respir Investig; 2017 Mar; 55(2):145-152. PubMed ID: 28274530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
